#USA #Cambridge #Biointelli #Scientific Signal Intelligence #Biointelli Predict

Biointelli Sets a New Standard with Scientific Signal Intelligence™

Biointelli Corporation, headquartered in Cambridge, Massachusetts, has recently unveiled a significant advancement in the field of life sciences: the Biointelli Predict platform. This groundbreaking initiative aims to redefine how commercial teams identify demand and opportunities within the life sciences sector. Leveraging the innovative concept of Scientific Signal Intelligence™ (SSI), Biointelli Predict enables organizations to foresee purchasing cycles before they become visible through conventional sales pipelines or CRM systems.

Understanding Scientific Signal Intelligence™

Unlike traditional sales intelligence platforms that rely on outdated methodologies such as static lead lists and web-based intent signals, Biointelli Predict harnesses a wealth of real-time scientific data. This data encompasses various aspects of the scientific record, including NIH and NSF grant awards, clinical trial expansions, publication rates in PubMed, patent filings with the USPTO, hiring trends in laboratories, and conference participation statistics.

Each data signal is evaluated through the lens of its rate of change—termed 'Delta.' By measuring these Deltas, commercial teams can pinpoint emerging demand up to 18 months in advance of standard CRM insights. As David Hines, the Founder and CEO of Biointelli, illustrates, “The scientific record is the most accurate leading indicator of life science demand ever assembled.”

Real-world Applications and Benefits

A telling example of Biointelli Predict’s functionality involves an oncology lab that receives a recent NIH grant. This lab typically experiences a surge in publication output, expands its workforce, and enhances conference participation. These factors suggest that the lab is entering a purchasing cycle for essential instruments and services. With the predictive capabilities of Biointelli Predict, commercial teams can engage potential buyers before they articulate their needs, significantly enhancing sales strategies. This early engagement enables teams to tailor their messaging and prioritize outreach, thus improving competitive positioning at the onset of the buying cycle.

Launch at AACR 2026

Biointelli Predict will be officially unveiled at the prestigious American Association for Cancer Research (AACR) Annual Meeting on April 17, 2026, in San Diego. At this event, attendees can witness firsthand how the platform indexes millions of scientific entities worldwide, with a particular focus on oncology. Biointelli Predict has meticulously catalogued over 17,000 companies and more than 500,000 academic laboratories.

The platform also features an extension known as BioConnect PRO, which assists in converting identified signals into a qualified sales pipeline through innovative GenAI-powered outreach strategies. This dual approach maximizes the potential of commercial engagements in the life sciences.

Intellectual Property and Compliance

Biointelli's pioneering methodologies are secure under a USPTO Provisional Patent Application (No. 63/998,284), which was filed on March 6, 2026. The application underscores Biointelli’s commitment to leading the charge in this new category of commercial intelligence in the life sciences sector.

Biointelli Predict will be available to a variety of stakeholders within the life sciences industry, including manufacturers, distributors, contract research organizations (CROs), and scientific services firms. The company has a history of collaboration with industry leaders such as Thermo Fisher Scientific and Danaher, providing reliable data and insights for over 14 years.

For those attending AACR 2026, Biointelli representatives will be present to provide demonstrations and answer queries about the platform's capabilities. Interested parties can schedule meetings or request demos through their official communication channels.

About Biointelli Corporation

Founded in 2008, Biointelli Corporation is dedicated to advancing life science by providing unrivaled commercial intelligence centered on Scientific Signal Intelligence™. The company's extensive dataset is built from 18 years of curated scientific data encompassing grants, publications, patents, purchasing data, and clinical trial activity, ensuring that clients have access to the most relevant and actionable insights. Biointelli's compliance with GDPR and CPPA principles reflects its commitment to ethical data practices, further empowering its customers with GenAI-powered commercial engagement tools.Potential clients and collaborators are encouraged to explore the capabilities of Biointelli Predict and engage with the platform at the upcoming AACR meeting.